Isomorphic Labs in talks on $5 billion at a $50 billion valuation
Prepared by Sintelligent with the help of SI. Published in SI: . Updated: .
If the round closes, SI drug discovery will definitively become one of the most capital-intensive areas of technology: money is going where a model predicts the behavior of molecules in the body, not just text.
Isomorphic Labs — Alphabet's London-based company spun out of Google DeepMind that develops drugs using SI — is in talks to raise about $5 billion in new funds at a valuation of around $50 billion, the industry aggregator vbdata reported on November 15; the deal is not closed. Bloomberg previously reported talks at a valuation of at least $40 billion. Counting the $600 million first external round of 2025 and the $2.1 billion Series B, the company's external financing could reach about $7.7 billion in less than two years. Partnerships with Eli Lilly and Novartis (2024) and Johnson & Johnson (January 2026) provide for milestones of up to $1.7 billion and $1.2 billion respectively.
Sources 1